Arsenic Trioxide and Reduced Anthracycline Dose in Pediatric Acute Promyelocytic Leukemia

In the phase III historically controlled Children’s Oncology Group (COG) AAML0631 trial, arsenic trioxide consolidation permitted the use of...


Convergence of Precision Medicine and Immuno-oncology

"The convergence of two very hot and interesting topics—precision medicine and immuno-oncology”—is being advanced by next-generation sequencing...

Hematologic Malignancies

Selected Abstracts on Novel Therapies for Hematologic Malignancies

The 22nd Congress of the European Hematology Association was held in June in Madrid, drawing hematologists and allied professionals...


More Top Stories

Colorectal Cancer

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Breast Cancer

MammaPrint Test Addressed in ASCO Breast Cancer Guideline Update

New recommendations on the use of the MammaPrint genomic test issued on July 10 will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the ASCO 2016 clinical practice guideline on the use of biomarkers in these patients. The...


AKT Inhibitor Ipatasertib in Metastatic Triple-Negative Breast Cancer

The randomized phase II LOTUS trial has shown improved progression-free survival with the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer. These results were reported by Kim et al in The Lancet Oncology. The PI3K/AKT...

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

Colorectal Cancer

New Data Reported on Vemurafenib, Vitamin D, Selective Internal Radiotherapy, and Circulating Tumor DNA in Colorectal Cancer

RESULTS OF the IDEA trial, which showed that some patients with stage III low-risk colon cancer may require less oxaliplatin therapy (see the June 25 issue of The ASCO Post), were among the findings highlighted at the 2017 ASCO Annual Meeting Plenary Session. Other studies of interest in colorectal ...

NYU Perlmutter Creates New Pancreatic Cancer Center

PERLMUTTER CANCER CENTER at NYU Langone has announced the creation of a multidisciplinary center of excellence to develop innovative approaches to diagnose, treat, and prevent pancreatic cancer. The new Pancreatic Cancer Center brings together laboratory researchers, surgeons, oncologists,...

Liquid Biopsies Identify Distinct Genomic Profiles With Potentially Targetable Alterations in Carcinoma of Unknown Primary

Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7% of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published by Kato et al in Cancer Research....

Supportive Care
Issues in Oncology

Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention

Issues in Oncology

Tissue Specimens in Clinical Trials: A Double-Edged Sword

AN INCREASING number of clinical trials require the submission of tissue specimens, either from archived specimens or increasingly from fresh biopsies taken after enrollment into the trial. These specimens can be either mandatory, required to determine whether a given patient has the required...


Detection of Early-Stage Cancers With Circulating Tumor DNA

In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...